1 / 42

DVT and PE

DVT and PE. Pathophysiology, prophylaxis, treatment Anton Sharapov. Cases to consider. 38 yom for elective IHR 65 yom for elective IHR 65 yom, obesity/CHF/prev DVT for IHR 25 yof post severe head injury 25 yom post trauma/abdo/chest 75 yof post hip # 65 yom post THA, obese.

liuz
Download Presentation

DVT and PE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. DVT and PE Pathophysiology, prophylaxis, treatmentAnton Sharapov

  2. Cases to consider • 38 yom for elective IHR • 65 yom for elective IHR • 65 yom, obesity/CHF/prev DVT for IHR • 25 yof post severe head injury • 25 yom post trauma/abdo/chest • 75 yof post hip # • 65 yom post THA, obese

  3. Scope of the problem • Common postop complication • Asymptomatic > symptomatic • Difficult to study • Most studies evaluate asymptomatic pts

  4. Epidemiology • VTE 48:100,000 • PE 69:100,000 • Incidence – 20-70% surgery pts • ½ begin in OR

  5. Epidemiology • DVT and PE – different stages of same disease process • 10% proximal DVTs progress to symptomatic PE • 25% distal DVTs become proximal

  6. Outcomes • Most asymptomatic VTE recover sans treatment and complications • Less then 1 in 8 confirmed clots progress to symptomatic thromboembolic disease • Important to observe clots over a period of time

  7. Outcomes of PE • Outcomes of PE are difficult to assess • Registry estimates are always higher then in clinical studies (7% vs 2%) • Mortality is a function of RV function, clot burden, and comorbidities • Risk of fatal PE greatest 3-7 postop • Asymptomatic PE are common • 40% of asymptomatic prox DVTs

  8. Assessment • Assess risk of DVT and risk of bleeding • Assess duration of prophylaxis • Assess Virchov triad • Venous stasis • Endothelial injury • hypercoagulability

  9. Risk factors: venous stasis • Immobility & tourniquet application • Institutionalization • CVA • Paralysis • CHF • Travel >4 hours • Obesity • Respiratory failure • Varicose veins • Duration/extent of postop immobilization

  10. Risk factors: endothelial injury • Trauma • Atherosclerosis • Perioperative • Malignancy • Post-phlebitic syndrome • Prior DVT • CV catheter • Inflamatory condition • Hyperhomocysteinemia

  11. Risk factors: hypercoagulability, Acquired • Post op • Malignancy • Hormone replacement • Estrogen therapy

  12. Risk factors: hypercoagulability, Acquired: • Antiphospholipid antibody • Lupus anticoagulant – 5-10 fold risk • Myeloproliferative d/o • Paroxysmal nocturnal hemoglobinuria • Nephrotic syndrome • Pn loosing enteropathy

  13. Risk factors: hypercoagulability, Inherited: • Factor V leiden – APC resistance • Absolute risk post op VTE is small - 1/100 • Relative risk increased (3-5 fold) • Screening not recommended • Antithrombin, pn C/S deficiency • Fibrinogen/TPA defects • Prothrombin gene mutation

  14. Risk factors: Miscelaneous • Use/nonuse of thrombopophylactic measures • Age - rises linearly after 40 • Ethnicity: • Asian/South Pacific - threefold lower • African American - slightly higher • Latin - slightly lower • Site/extent traumatic injury • Knee/spine=major trauma>hip>uro/gyny> neuro>general/thoracic

  15. Risk of DVT, miscellaneous • Surgical procedure - most important • Neurosurgery & ortho - 6% & 3% • Major vascular • Bowel, bladder, gastric bypass and kidney transplant • Radical neck, IHR, lap chole (0.3%),TURP, thyroid/parathyroid - lowest risk

  16. Need for global integrative assessment • American College of Chest Physicians • Risk stratification tool • Problems: • What defines major vs minor surgeries? • No weighting of Risk Factors • Why age 40 and 60 important?

  17. Risk of bleeding • Bleeding d/o • Use of antiplatelet meds • Previous GI bleed • Cancer • Hepatic/renal insufficiency • ?age

  18. VTE prophylaxis: what’s available? • Intermittent compression devise • Stockings • ASA 80-325 mg • UF heparin 5000 bid, tid • LMW bid • Warfarin • Anti – Xa pentasaccharide (fondaparinix)

  19. Efficacy of mechanical VTE prophylaxis

  20. Early ambulation • Routine for all pts • Acceptable as sole mode for low risk • Useful adjunct esp post knee/hip surgery

  21. Elastic stockings • First shown to work in 1952 • Decrease venous pooling • Evidence of benefit for mod/high risk, but used only as adjunct • Harmful if not work correctly

  22. ICD • Work very well • Not useful form BMI >25 • Only effective if used correctly and continuously when pt not ambulating • Have potential to reduce ambulation • Recommended in mod-high risk gyn surgery as solo • Not recommended as sole mode in • Highest risk – except neurosurgery • High risk urological • Hip and knee surgery

  23. IVC • For absolute contraindication of anticoagulation • For life-threatening hem on AC • For failure of AC • Used to prevent fatal PE • Temporary filters preferred • If left in place, cause DVTs

  24. Efficacy of pharmacological VTE prophylaxis

  25. Aspirin • Not recommended as sole prophylaxis • Beneficial post hip-fracture • 160 mg OD, 5/52, 13,000 pts • Combined with routine prophylaxis • PE – 0.7 vs 1.2 • Fatal PE 18 vs 43

  26. UF heparin • Good for moderate risk gen surgery • Modest increase in bleeding • Compared to LMWH (2.65% vs 1.8%) • Additive effect of stockings and ICD] • Risk of HIT

  27. warfarin • For very high risk with lower extremity orthopedic and neuro surgery • For gen surgery other methods work just as well… • Good for extended prophylaxis • Delayed onset of action, may start preop! • Recommended for • Hip #, THA, TKA

  28. LMW heparin and Pentasaccharideds • Preferential inhibition of factor Xa • FDA approved for DVT prophylaxis • Not FDA approved as of yet for DVT prophylaxis in pregnancy, spinal cord injury, trauma, neurosurgery… but are being used

  29. LMW heparin and Pentasaccharideds cont’d • Effective for mod risk general surgery • Gyn/obs • second line to mechanical • Trauma • Method of choice only if risk of bleeding is not significant. If it is – stocking+/-ICD • Recommended for ortho lower extremity surgery • Fondoparinix reduces asymptomatic DVTs only…

  30. LMW heparin and Pentasaccharideds cont’d • Risk of epidural hematoma • Strategies • Avoid regional anesth in those prone to bleed • Needle in 12 h after onset of LMWH • Single dose anesthetic better then infusion • D/c cath in 12 h • No dosing of LMWH within 2 h of cath d/c

  31. Direct thrombin inhibitors • Effective in initial studies • Comparable to LMWH • For HIT pts

  32. Duration of prophylaxis • Start immediately after or prior to surgery • 7-10 days post • Warfarin may be started 10/7 prior but INR should be less then 1.5 • Argument for prolonged (30 day) prophylaxis for high risk. DVT incidence • sympt – 3% vs 1% on treatment • Asympt – 19% vs 9% on treatment

  33. Prolonged prophylaxis • Orthopedics • Post THA for 4-6 weeks with LMWH or warfarin, especially with Risk Factors • Obesity, sedentary, prior DVT • General surgery • Prolonged treatement with LMWH prevents out-pt DVTs but at a marginal cost that was deemed inappropriate

  34. Screening for DVT? • Not in the asymptomatic pts….

  35. Diagnostic strategy of DVT • Suspect • Dupplex • For proximal or ANY symptomatic – treat • For distal AND asymptomatic – follow with serial duplex US

  36. Accuracy of Tests for Diagnosis of PE • Clinical suspicion is paramount

  37. Diagnostic strategy for PE • Suspect • VQ • If normal AND D-Dimer low – ruled out • If high probability – start treatment • If indeterminate/nondiagnostic – angio, angio CT

  38. Treatment • IV heparin, aPTT 1.5- 2.3 normal 5/7 • May use LMW • Coumadin INR 2-3 • Overlap heparin and warfarin 4/7 • On warfarin 3-6/12 • Consider ECHO/trop to evaluate RVF for PE to id High Risk pts.

  39. Treatment • Hemodynamically unstable PE may require pressure support, fluid status monitoring, and/or thromolysis / surgery

  40. Cases to consider • 38 yom for elective IHR • None, low risk • 65 yom for elective IHR • Moderate risk, Consider UN heparin pre-op, ambulation, stockings post op • 50 yom, obesity/CHF/prev DVT for IHR • High risk, consider LMWH preop/post op. Conisder warfarin

  41. Cases concluded • 25 yof post severe head injury • High risk, mechanical, • 25 yom post trauma/abdo/chest • High risk, mechanical initially, consider LMWH when risk of bleeding is low • 75 yof post hip # • High, consider LMWH periop, warfarin or aspirin post op • 65 yom post THA, obese • High, consider LMWH periop, warfarin or aspirin post op

More Related